A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Metastatic Urothelial Carcinoma · Locally Advanced Urothelial Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 38 (planned)
- Started
- Jul 17, 2024
- Main results expected
- Mar 31, 2028
- Fully finished
- Mar 31, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Percentage of Participants with Dose-limiting toxicities (DLT)
Measured over: Up to 21 days
Part 1: Percentage of Participants Who Experienced At Least One Adverse Event (AE)
Measured over: Up to ~3 years
Part 1: Percentage of Participants Who Discontinued Study Treatment Due to an AE
Measured over: Up to ~2 years
Part 2: Percentage of Participants with DLT
Measured over: Up to 21 days
Part 2: Percentage of Participants Who Experienced At Least One AE
Measured over: Up to ~3 years
Part 2: Percentage of Participants Who Discontinued Study Treatment Due to an AE
Measured over: Up to ~2 years
Part 2: Objective Response Rate (ORR)
Measured over: Up to ~3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06483334 · record last updated 2026-02-18 · checked 2026-11-09 15:47 UTC